Results 1 to 10 of about 2,642 (145)
Validation of 19-items wearing-off (WOQ-19) questionnaire to Portuguese [PDF]
Arquivos de Neuro-Psiquiatria, 2020 Background: The treatment of Parkinson disease with dopaminergic therapy improves functionality and quality of life. However, as the disease progresses, the wearing-off phenomenon develops.
Carlos Eduardo MANTESE +3 more
doaj +1 more source
Arquivos de Neuro-Psiquiatria, 2022 The treatment of Parkinson's disease (PD) is challenging, especially since it is considered highly individualized. The Brazilian Academy of Neurology has recognized the need to disseminate knowledge about the management of PD treatment, adapting the best
Roberta Arb Saba +21 more
doaj +1 more source
Prescribing patterns of antiparkinson drugs in a group of Colombian patients, 2015
Biomédica: revista del Instituto Nacional de Salud, 2018 Introduction: Parkinson’s disease, whose prevalence in Colombia is 4.7 per 1,000 inhabitants, is a public health problem and a therapeutic challenge for health professionals. Objective: To determine the prescribing patterns of antiparkinson drugs and the
Jorge Enrique Machado-Alba +3 more
doaj +1 more source
Fall-related injuries in a nursing home setting: is polypharmacy a risk factor?
BMC Health Services Research, 2009 Background Polypharmacy is regarded as an important risk factor for fallingand several studies and meta-analyses have shown an increased fall risk in users of diuretics, type 1a antiarrhythmics, digoxin and psychotropic agents.
Colli Cristiano +8 more
doaj +1 more source
GE: Portuguese Journal of Gastroenterology, 2017 The continuous delivery of a levodopa/carbidopa gel suspension (Duodopa®) into the small bowel through a jejunal tube inserted via percutaneous endoscopic gastrostomy represents a new treatment method in advanced Parkinson disease.
Pedro Russo +6 more
doaj +1 more source
Pharmacy Practice, 2018 Objective: The objective of this study is to compute the potential benefit of Pramipexole ER on total levodopa equivalent dose (LED) and Unified Parkinson Disease Rating Score (UPDRS-III) compared to mono- or combined therapy of pramipexole IR and/or ...
Faddoul L +5 more
doaj +1 more source
Sustained Release Antiparkinson Agents: Controlled Release Levodopa [PDF]
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 1992 ABSTRACT:The rationale for sustained release oral levodopa preparations is to deliver levodopa in the areas of maximal intestinal absorption in a slow and predictable way, leading to stable plasma levodopa levels and brain dopamine levels, therefore resulting in a lengthened duration of action.
S, Gauthier, D, Amyot
openaire +2 more sources
Frontiers in Neurology, 2019 Parkinson's disease (PD) is a neurodegenerative disease characterized by progressive loss of dopaminergic neurons, appearance of Lewy bodies and presence of neuroinflammation.
Elisa Storelli +4 more
doaj +1 more source
Anticonvulsant Activity of Antiparkinsonism Agents
Experimental Biology and Medicine, 1968 SummaryThe anticonvulsant activity of synthetic antiparkinsonism agents has been studied in mice with experimental seizures and in children with myoclonic spasms refractory to conventional medications. Procyclidine and trihexyphenidyl protected mice from maximal electroshock seizures.
J G, Millichap +2 more
openaire +2 more sources
Evidence-based guidelines for the antipsychotic drugs: Schizophrenia
Psychiatry and Clinical Psychopharmacology, 2021 Antipsychotic medications, as the standard pharmacologic treatment of schizophrenia, are used to decrease symptoms and to increase functioning. The currently available antipsychotics are all significantly efficacious for positive symptoms.
Özcan Uzun
doaj